ARDS, Human Clinical Trial
Official title:
The Effects of Low Flow Extracorporeal CO2 Removal on Mechanical Power in ARDS Patients
NCT number | NCT03939260 |
Other study ID # | 13175/2019 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 20, 2019 |
Est. completion date | March 2024 |
Although mechanical ventilation remains the cornerstone of ARDS treatment, several experimental and clinical studies have undoubtedly demonstrated that it can contribute to high mortality through the developing of ventilator induced lung injury even in patients with plateau pressure <30 cmH2O. Since now there are no studies exploring the application of low flow extracorporeal CO2 removal and ultraprotective ventilation to reduce mechanical power, a composite index of VILI, independently from the value of plateau pressure or the severity of hypercapnia.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | March 2024 |
Est. primary completion date | March 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: ARDS patients undergoing mechanical ventilation with: - PaO2/FiO2 <150 with a level of positive end expiratory pressure (PEEP) of 10 cmH2O or higher with a FiO2 > 0.5 - Plateau pressure of 28 cmH2O or higher with tidal volume of 6 ml/Kg of ideal body weight - Mechanical power of 18 J/min or higher. Exclusion Criteria: - <18 years of age - Pregnancy - Obesity with BMI> 30 - Platelets <30 G/l - Decompensated heart failure or acute coronary syndrome - Acute brain injury - Contraindication for systemic anticoagulation (for example, gastrointestinal bleeding, recent cerebrovascular accident, or chronic bleeding disorder, recent major surgery) - Patient moribund, decision to limit therapeutic interventions - Catheter access to femoral vein or jugular vein impossible - Pneumothorax. |
Country | Name | City | State |
---|---|---|---|
Italy | ASST-Santi Paolo e Carlo, San Paolo Hospital | Milan |
Lead Sponsor | Collaborator |
---|---|
University of Milan |
Italy,
Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8. — View Citation
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350. — View Citation
Chiumello D, Brochard L, Marini JJ, Slutsky AS, Mancebo J, Ranieri VM, Thompson BT, Papazian L, Schultz MJ, Amato M, Gattinoni L, Mercat A, Pesenti A, Talmor D, Vincent JL. Respiratory support in patients with acute respiratory distress syndrome: an expert opinion. Crit Care. 2017 Sep 12;21(1):240. doi: 10.1186/s13054-017-1820-0. Review. — View Citation
Cressoni M, Gotti M, Chiurazzi C, Massari D, Algieri I, Amini M, Cammaroto A, Brioni M, Montaruli C, Nikolla K, Guanziroli M, Dondossola D, Gatti S, Valerio V, Vergani GL, Pugni P, Cadringher P, Gagliano N, Gattinoni L. Mechanical Power and Development of Ventilator-induced Lung Injury. Anesthesiology. 2016 May;124(5):1100-8. doi: 10.1097/ALN.0000000000001056. — View Citation
Fan E, Needham DM, Stewart TE. Ventilatory management of acute lung injury and acute respiratory distress syndrome. JAMA. 2005 Dec 14;294(22):2889-96. Review. — View Citation
Gattinoni L, Tonetti T, Cressoni M, Cadringher P, Herrmann P, Moerer O, Protti A, Gotti M, Chiurazzi C, Carlesso E, Chiumello D, Quintel M. Ventilator-related causes of lung injury: the mechanical power. Intensive Care Med. 2016 Oct;42(10):1567-1575. doi: 10.1007/s00134-016-4505-2. Epub 2016 Sep 12. — View Citation
Kolobow T, Gattinoni L, Tomlinson T, Pierce JE. An alternative to breathing. J Thorac Cardiovasc Surg. 1978 Feb;75(2):261-6. — View Citation
Peek GJ, Clemens F, Elbourne D, Firmin R, Hardy P, Hibbert C, Killer H, Mugford M, Thalanany M, Tiruvoipati R, Truesdale A, Wilson A. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res. 2006 Dec 23;6:163. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mechanical Power reduction. | Achievement of Mechanical Power reduction under 18 J/min while maintaining pH and PaCO2 to ± 20% of baseline values obtained at tidal volume of 6 mL/kg. Mechanical Power (MP) (J/min) = 0.098 * respiratory rate * tidal volume (inspiratory peak airway pressure - 1/2 * (airway pressure at end inspiratory pause - airway pressure at PEEP)) |
Changes from baseline to day 5. | |
Secondary | Respiratory mechanics. | 1. Respiratory system elastance (Ers) (cmH2O/L) = (airway pressure at end inspiratory pause - airway pressure at PEEP) / tidal volume | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Respiratory mechanics. | 2. Lung elastance (El) (cmH2O/L) = (transpulmonary pressure at end inspiratory pause - transpulmonary pressure at PEEP / tidal volume | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Respiratory mechanics. | 3. Chest wall elastance (Ecw) (cmH2O/L) = (esophageal pressure at end inspiratory pause - esophageal pressure at PEEP) / tidal volume | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Respiratory mechanics. | 4. End inspiratory transpulmonary pressure (cmH2O)= airway pressure at end inspiratory pause - (esophageal pressure at end inspiratory pause - expiration at atmospheric pressure by a release manouvre). | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Gas exchange. | Assessment of changes in PaCO2 mmHg. | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Gas exchange. | Assessment of changes in PaO2 mmHg. | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Gas exchange. | Assessment of changes in PaO2/FiO2. | Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days | |
Secondary | Safety assessment and adverse device related events: frequency of serious adverse events | Safety assessment reporting frequency of serious adverse events in terms of device related mechanical events (Pump malfunction, membrane lung clotting, system leaks, tubing rupture, air in the circuit) and device related clinical events (heamolysis, significant bleeding, thromboembolic complications, neurologic complications, metabolic complications). | Every day, until the fifth day or until the weaning from ECCO2R if lower than five days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06444750 -
Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
|
||
Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04274296 -
Advisory Lead ARDS Respirator Management
|
||
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
Recruiting |
NCT03215316 -
Screening Expiratory Flow Limitation by Flow-time Curve
|
N/A | |
Recruiting |
NCT04115514 -
Treatment of ARDS With Instilled T3
|
Phase 2 | |
Not yet recruiting |
NCT05061212 -
The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
|
||
Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
Not yet recruiting |
NCT04556864 -
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
|
||
Recruiting |
NCT04174014 -
Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography
|
N/A | |
Enrolling by invitation |
NCT06164639 -
Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
|
||
Terminated |
NCT05384379 -
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
|
Early Phase 1 | |
Completed |
NCT04375735 -
London's Exogenous Surfactant Study for COVID19
|
Phase 1/Phase 2 | |
Completed |
NCT06224010 -
Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
|
||
Not yet recruiting |
NCT04530188 -
Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS
|
Phase 3 | |
Completed |
NCT03405038 -
Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
|
||
Recruiting |
NCT05148026 -
Regional Citrate Anticoagulation for RRT During V-V ECMO
|
N/A | |
Recruiting |
NCT04390360 -
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
|
N/A | |
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|